Lineage Cell Therapeutics, Inc. LCTX
1.03
0.08
8.42%
as of 25 Sep
- Market cap
- $239.7M
- P/E
- 0.0×
Follow LCTX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
35.76 | 26.40 | 26.20 | 24.98 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(106.96) | (78.78) | (47.93) | (45.12) | |
P/B ratio |
18.60 | 8.87 | 7.35 | 5.47 | |
Price to Tangible BV |
0.00 | 394.55 | 37.50 | 18.76 | |
EV/Sales |
32.02 | 22.57 | 22.59 | 21.10 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(16.99) | (17.37) | (15.10) | (11.59) | |
EV/FCF |
(16.59) | (16.90) | (14.78) | (11.32) | |
Quick Ratio |
4.33 | 4.99 | 6.65 | 6.44 | |
Current Ratio |
4.50 | 5.20 | 6.89 | 6.61 | |
Net Debt/EBITDA |
11.36 | 8.74 | 7.21 | 5.85 | |
Debt/Assets |
0.04% | 0.03% | 0.02% | 0.01% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.12 | 0.13 | 0.13 | 0.13 | |
Operating CF/Net income |
0.12 | (5.73) | 1.68 | (4.89) | |
Capex/Depreciation |
(0.05) | (2.36) | (0.29) | (0.45) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
88.86% | 124.67% | 245.45% | 446.59% | |
Selling, General and Administrative Expense of Revenue |
113.85% | 73.43% | 294.72% | 488.12% | |
Intangible Assets out of Total Assets |
0.47 | 0.38 | 0.39 | 0.40 | |
Share Based Compensation of Revenue |
32.57% | 16.62% | 67.94% | 149.77% | |
Graham Net Nets |
(0.07) | (0.03) | 0.00 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(17.16%) | (16.77%) | (17.72%) | (10.98%) | |
Free Cash Flow Yield |
(5.40%) | (5.06%) | (5.84%) | (7.46%) | |
Revenue per Share |
0.02 | 0.03 | 0.01 | 0.00 | |
Operating CF per Share |
(0.02) | (0.02) | (0.03) | (0.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.02) | (0.03) | (0.03) | |
Cash per Share |
0.18 | 0.24 | 0.22 | 0.20 | |
Shareholders Equity per Share |
0.09 | 0.19 | 0.22 | 0.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.09 | 0.19 | 0.22 | 0.24 | |
Free Cash Flow |
(3.63) | (5.28) | (8.13) | (7.35) | |
Working Capital |
32.88 | 47.79 | 48.02 | 44.95 | |
Capital Expenditures |
(0.01) | (0.40) | (0.05) | (0.11) | |
Net Current Asset Value |
(26.58) | (10.08) | (0.67) | 6.55 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.06 | 0.03 | 0.10 | |
Net Profit Margin |
(809.05%) | 12.88% | (278.96%) | 138.63% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.27 | 0.76 | 0.51 | 0.52 | |
Average Payables |
4.51 | 6.31 | 5.27 | 4.92 | |
Average Assets |
93.12 | 112.90 | 110.64 | 98.51 | |
Average Common Equity |
42.80 | 60.18 | 65.18 | 53.46 |
Columns are period end dates